Tin tức & Cập nhật

$Tirabrutinib safe, effective for refractory pemphigus$

Tirabrutinib safe, effective for refractory pemphigus

30 Oct 2021

Tirabrutinib induces remission and lowers oral corticosteroid exposure among patients with refractory pemphigus, a recent study has found.

Tirabrutinib safe, effective for refractory pemphigus

30 Oct 2021

Novel JAK3 blocker: Potential to stave off balding?

22 Oct 2021 bởi

The oral selective Janus kinase 3 (JAK3) inhibitor ritlecitinib effectively prevents hair loss in people with alopecia areata (AA) compared with placebo, according to the ALLEGRO study presented at EADV 2021.

Novel JAK3 blocker: Potential to stave off balding?

22 Oct 2021

$Oral Bruton’s tyrosine kinase inhibitor shows therapeutic potential in refractory pemphigus$

Oral Bruton’s tyrosine kinase inhibitor shows therapeutic potential in refractory pemphigus

22 Oct 2021

B-cell signalling suppression with tirabrutinib appears to promote remission in patients with refractory pemphigus, as shown in a phase II trial. Furthermore, treatment has reduced oral corticosteroid exposure over time without any major safety concerns.

Oral Bruton’s tyrosine kinase inhibitor shows therapeutic potential in refractory pemphigus

22 Oct 2021

Bimekizumab maintains skin clearance in patients with plaque psoriasis

22 Oct 2021 bởi

Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.

Bimekizumab maintains skin clearance in patients with plaque psoriasis

22 Oct 2021

Onychomycosis worsens quality of life, warrants effective treatments

21 Oct 2021

Onychomycosis has a substantial impact on the quality of life of patients and requires effective treatment, results of a systematic review have confirmed.

Onychomycosis worsens quality of life, warrants effective treatments

21 Oct 2021

Substandard reporting of endpoints mars dermatology trials

20 Oct 2021

In recent dermatology literature, the quality of primary endpoint reporting of randomized controlled trials (RCTs) remains below average, according to the results of a recent study.

Substandard reporting of endpoints mars dermatology trials

20 Oct 2021

ESRD, hyperparathyroidism tied to penile calciphylaxis

20 Oct 2021

A recent study that defined the disease course of penile calciphylaxis has reported high mortality among patients with such condition and suggests imaging to aid in its diagnosis. End-stage renal disease, hyperparathyroidism, and normal body mass index are significantly associated with this rare disorder.

ESRD, hyperparathyroidism tied to penile calciphylaxis

20 Oct 2021

Roflumilast cream eases itch burden, severity in chronic plaque psoriasis

19 Oct 2021 bởi

In patients with chronic plaque psoriasis, once-daily treatment with roflumilast improved severity and burden of itch compared with vehicle cream, according to results of the phase III DERMIS-1 and DERMIS-2 trials presented at EADV 2021.